Can Oral Pills Dominate the GLP-1 Market? Novo Nordisk’s Bold Prediction for 2030

Novo Nordisk predicts oral GLP-1s will reshape the weight-loss drug landscape

Novo Nordisk has revised its market forecast significantly upward, predicting that oral GLP-1 medications will capture more than one-third of the global GLP-1 market by 2030-a larger share than the company originally anticipated.[2][4] This shift reflects growing confidence in the commercial potential of pill-based obesity treatments as an alternative to injectable therapies that have dominated the market to date.

The Launch of Oral Wegovy: A Turning Point

The company launched the daily oral version of Wegovy in the United States earlier this month at a starting price of $149 per month.[2] This marks the first FDA approval of an oral GLP-1 medication for weight loss, positioning Novo Nordisk as the first-mover in an emerging segment of the obesity drug market.[3] The oral formulation uses the same active ingredient (semaglutide)as the injectable versions Ozempic and Wegovy, but in a delivery mechanism designed to address a key barrier to treatment adoption: needle anxiety and injection burden.

Why the Market Shift Matters

Emil Kongshøj Larsen, executive vice president for product and portfolio strategy at Novo Nordisk, explained the revised forecast at the JPMorgan Healthcare Conference in San Francisco.[4] According to Larsen, the company’s updated view reflects a better understanding of patient behavior in an increasingly consumer-driven obesity market.[2] The shift to oral therapies is expected to reach patient populations historically underrepresented in GLP-1 use, including men and younger patients who may have avoided or discontinued injection-based treatments.[2][4]

Larsen emphasized that oral medications lower the threshold for primary care prescribing, potentially accelerating diagnosis and treatment at earlier stages of disease.[3] He also highlighted that pricing will be a decisive factor for patient access, noting that price reductions require expanded manufacturing capacity – a commitment Novo Nordisk has underscored through its acquisition of Catalent, a contract manufacturer.[4]

The Competitive Landscape: Cautious Optimism Amid Market Pressure

Despite Novo Nordisk’s first-mover advantage, analyst projections suggest the competitive outlook will be more complex. Goldman Sachs forecasts that oral GLP-1s will capture approximately $22 billion, or 24% of the global weight-loss drug market by 2030.[3] However, within that oral segment, the bank projects that Eli Lilly’s orforglipron will dominate with roughly 60% market share ($13.6 billion), while Novo’s oral semaglutide is expected to capture about 21% ($4 billion).[3]

This projection reflects lessons from Novo Nordisk’s prior experience with Rybelsus, the first oral GLP-1 approved for diabetes in 2019. Despite comparable clinical efficacy to the injectable Ozempic, Rybelsus generated approximately $2.7 billion in sales in 2023 compared to nearly $14 billion for Ozempic – roughly a 5:1 gap between drugs with identical active ingredients.[3] Rybelsus accounted for just 14% of the GLP-1 market share by the end of 2023, a cautionary tale about the challenges of oral drug delivery.[3]

Factors Driving the Shift Toward Oral Formulations

Patient Convenience and Adherence: Oral medications eliminate the need for injections, potentially improving patient compliance and expanding treatment to populations with needle anxiety.[3][5]

Manufacturing and Supply Scalability: Oral formulations may offer advantages in manufacturing and distribution, though manufacturing constraints remain a concern. The company has prioritized expanding production capacity to support broader access and potentially lower pricing.[4]

Market Accessibility: Lower pricing enabled by oral delivery and expanded manufacturing could dramatically increase treatment availability, particularly in primary care settings where injectable administration may be less practical.[3][4]

Clinical and Commercial Considerations

Oral semaglutide demonstrates weight-loss efficacy and safety on par with injectable formulations, according to accumulated prescribing data.[4] However, oral GLP-1s face bioavailability challenges that injectables do not. The need for specific dosing instructions – such as taking medications on an empty stomach and waiting before eating – may limit the convenience advantage compared to injectable competitors with fewer restrictions. [3]

Goldman Sachs analysts expect the remaining 19% of the oral GLP-1 market to be distributed among emerging pills from Viking Therapeutics, Structure Therapeutics, AstraZeneca, Roche, and Pfizer, all in development.[3] In this crowded competitive landscape, the difference between “take anytime” and “take on an empty stomach and wait” may prove decisive for market positioning.[3]

Market Size and Financial Projections

The overall weight-loss drugs market is estimated to reach approximately $95 billion to $150 billion by 2030, depending on the source.[2][3] Within that market, oral GLP-1s are projected to represent a significant but not dominant share – somewhere between 24% and one-third by most analyst estimates. However, Novo Nordisk’s internal forecast of over one-third suggests the company believes adoption will exceed current consensus expectations.[2][4]

What Happens Next

Novo Nordisk plans to continue expanding its GLP-1 pipeline, exploring more than 20 pipeline assets with diverse mechanisms, including RNA and small molecule therapies.[4] The company is also pursuing expanded indications beyond obesity, including cardiovascular disease, chronic kidney disease, and metabolic dysfunction-associated steatohepatitis (MASH), for which it recently won U.S. approval.[4]

Broader oral GLP-1 availability is expected in the first half of 2026 as additional candidates advance through regulatory review.[5] The company has also indicated a focus on geographic expansion, with discussions about potential population-level health impacts in markets like South Korea, where GLP-1 uptake has already shown measurable effects on body mass index curves.[4]

Why This Matters for Patients

If oral GLP-1s achieve market penetration approaching one-third of the market, the implications for patient access could be substantial. Easier administration may encourage earlier treatment initiation and longer adherence, potentially changing the trajectory of obesity treatment in primary care. However, the success of this transition depends critically on pricing strategies and manufacturing capacity. Lower costs could extend treatment to millions of patients currently priced out of the market, while supply constraints could limit availability regardless of patient demand.

References

• American Journal of Managed Care. (n.d.). FDA approves oral semaglutide as first GLP-1 pill for weight loss. https://www.ajmc.com/view/fda-approves-oral-semaglutide-as-first-glp-1-pill-for-weight-loss[5]
• Food and Drug Administration. (n.d.). FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or[4]
• Morningstar. (n.d.). Novo and Lilly: FDA approval of Wegovy pill launches new obesity battle. https://global.morningstar.com/en-nd/stocks/novo-lilly-fda-approval-wegovy-pill-launches-new-obesity-battle[3]
• Novo Nordisk. (n.d.). Press releases. https://www.novonordisk.com/news-and-media/news-and-ir-materials.html[6]
• Pharmaceutical Commerce. (n.d.). FDA approves Novo Nordisk’s Wegovy pill. https://www.pharmaceuticalcommerce.com/view/fda-approves-novo-nordisk-wegovy-pill[2]
• Pharmaceutical Executive. (n.d.). FDA approves Novo Nordisk’s Wegovy pill for weight management. https://www.pharmexec.com/view/fda-approves-novo-nordisk-wegovy-pill-for-weight-management[1]
• Wegovy. (n.d.). Wegovy. https://www.wegovy.com/home.html[8]